HomeCompareBYLTF vs ABBV

BYLTF vs ABBV: Dividend Comparison 2026

BYLTF yields 1031.46% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BYLTF wins by $24699148.49M in total portfolio value
10 years
BYLTF
BYLTF
● Live price
1031.46%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24699148.59M
Annual income
$20,743,118,098,407.43
Full BYLTF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BYLTF vs ABBV

📍 BYLTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBYLTFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BYLTF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BYLTF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BYLTF
Annual income on $10K today (after 15% tax)
$87,674.06/yr
After 10yr DRIP, annual income (after tax)
$17,631,650,383,646.32/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BYLTF beats the other by $17,631,650,362,590.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BYLTF + ABBV for your $10,000?

BYLTF: 50%ABBV: 50%
100% ABBV50/50100% BYLTF
Portfolio after 10yr
$12349574.35M
Annual income
$10,371,559,061,589.59/yr
Blended yield
83.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BYLTF
No analyst data
Altman Z
-5.1
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BYLTF buys
0
ABBV buys
0
No recent congressional trades found for BYLTF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBYLTFABBV
Forward yield1031.46%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$24699148.59M$102.3K
Annual income after 10y$20,743,118,098,407.43$24,771.77
Total dividends collected$24398173.42M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BYLTF vs ABBV ($10,000, DRIP)

YearBYLTF PortfolioBYLTF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$113,846$103,145.95$11,550$430.00+$102.3KBYLTF
2$1,219,268$1,097,453.18$13,472$627.96+$1.21MBYLTF
3$12,289,209$10,984,591.99$15,906$926.08+$12.27MBYLTF
4$116,621,917$103,472,463.22$19,071$1,382.55+$116.60MBYLTF
5$1,042,478,098$917,692,646.52$23,302$2,095.81+$1042.45MBYLTF
6$8,782,006,243$7,666,554,678.34$29,150$3,237.93+$8781.98MBYLTF
7$69,755,917,071$60,359,170,391.34$37,536$5,121.41+$69755.88MBYLTF
8$522,709,788,987$448,070,957,720.61$50,079$8,338.38+$522709.74MBYLTF
9$3,697,224,757,719$3,137,925,283,502.65$69,753$14,065.80+$3697224.69MBYLTF
10$24,699,148,589,166$20,743,118,098,407.43$102,337$24,771.77+$24699148.49MBYLTF

BYLTF vs ABBV: Complete Analysis 2026

BYLTFStock

Baylin Technologies Inc., together with its subsidiaries, researches, designs, develops, manufactures, and sells passive and active radio frequency (RF) products, satellite communications products, and supporting services. It offers embedded antennas for use in smartphones, tablets, and other mobile devices; device-specific antennas for Wi-Fi routers; gateway devices for smart home connectivity, set-top boxes, and land mobile radio products; and indoor and outdoor distributed antenna systems (DAS), small cell system antennas, and base station antennas (BSA) for original equipment manufacturer, DAS, BSA, and small cell markets. The company also provides RF components, including GaN-based power amplifiers, gallium arsenide-based power amplifiers, indoor and outdoor frequency converters, and transceivers; microwave components comprising point-to-point microwave radios and network management software; fixed and mobile antennas, and antenna controllers for customers in the broadcast, maritime and cruise ships, government and military, homeland security, direct-to-home satellite, oil and gas, and wireless communications verticals. In addition, it offers RF and microwave solid state power amplifiers; and pulsed amplifiers for radar applications, and transmitter and transceiver products, as well as RF passive components and systems. The company offers its products under the Galtronics, Advantech Wireless, Alga Microwave, and Mitec VSAT brands. It operates in the United States, Vietnam, China, India, Thailand, South Korea, Canada, Sweden, Indonesia, Hungary, Taiwan, Philippines, Portugal, Romania, Japan, Brazil, Israel, Singapore, Australia, France, Germany, Russia, and internationally. The company was founded in 1978 and is headquartered in Toronto, Canada.

Full BYLTF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BYLTF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BYLTF vs SCHDBYLTF vs JEPIBYLTF vs OBYLTF vs KOBYLTF vs MAINBYLTF vs JNJBYLTF vs MRKBYLTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.